Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000

BMC Pharmacology

Volumn 8, Issue , 2008, Pages

  Gao, Zhan Gou ^a   Ye, Kai ^b   Göblyös, Anikó ^b   IJzerman, Adriaan P ^b   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 6 N (3 IODOBENZYL)ADENOSINE; 2 CHLORO 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLURONAMIDE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE 5' N ETHYLURONAMIDE; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; IMIDAZOQUINOLINE DERIVATIVE; LUF 6000; N (3,4 DICHLOROPHENYL) 2 CYCLOHEXYL 1H IMIDAZO[4,5 C]QUINOLIN 4 AMINE; UNCLASSIFIED DRUG; 2 CHLORO N(6) (3 IODOBENZYL) 5' N METHYLCARBOXAMIDOADENOSINE; 2-CHLORO-N(6)-(3-IODOBENZYL)-5'-N-METHYLCARBOXAMIDOADENOSINE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); AMINOQUINOLINE DERIVATIVE; DRUG DERIVATIVE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); IMIDAZOLE DERIVATIVE; N (3,4 DICHLOROPHENYL) 2 CYCLOHEXYL 1H IMIDAZO(4,5 C)QUINOLIN 4 AMINE; N-(3,4-DICHLOROPHENYL)-2-CYCLOHEXYL-1H-IMIDAZO(4,5-C)QUINOLIN-4-AMINE;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING ASSAY; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TRANSFORMATION; FEMALE; MATHEMATICAL MODEL; NONHUMAN; ANIMAL; BINDING COMPETITION; CRICETULUS; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HAMSTER; HUMAN; METABOLISM; RADIOASSAY; THEORETICAL MODEL;

ADENOSINE; ADENOSINE-5'-(N-ETHYLCARBOXAMIDE); ALLOSTERIC REGULATION; AMINOQUINOLINES; ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; IMIDAZOLES; MODELS, THEORETICAL; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A3;

EID: 58549095278     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-8-20     Document Type: Article

References (37)

1. Fredholm BB IJzerman AP Jacobson KA Klotz KN Linden J International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors Pharmacol Rev 2001, 53:527-552. 11734617
2. Chen Y Corriden R Inoue Y Yip L Hashiguchi N Zinkernagel A Nizet V Insel PA Junger WG ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors Science 2006, 314:1792-1795. 10.1126/science.1132559 17170310
3. Jacobson KA Gao ZG Adenosine receptors as therapeutic targets Nat Rev Drug Disc 2006, 5:247-264. 10.1038/nrd1983
4. Yan L Burbiel JC Maass A Müller CE Adenosine receptor agonists: from basic medicinal chemistry to clinical development Expert Opin Emerg Drugs 2003, 8:537-576. 10.1517/14728214.8.2.537 14662005
5. Gao ZG Jacobson KA Emerging adenosine receptor agonists Expert Opin Emerging Drugs 2007, 12:479-492. 10.1517/14728214.12.3.479
6. Christopoulos A Allosteric binding sites on cell-surface receptors: novel targets for drug discovery Nat Rev Drug Disc 2002, 1:198-210. 10.1038/nrd746
7. Soudijn W van Wijngaarden I IJzerman AP Allosteric modulation of G protein-coupled receptors: Perspectives and recent developments Drug Discov Today 2004, 9:752-758. 10.1016/S1359-6446(04)03220-9 15450241
8. Birdsall NJM Ligands interacting with G protein coupled receptors Celltransmission 2005, 20:1-8.
9. Kenakin T New concepts in drug discovery: Collateral efficacy and permissive antagonism Nat Rev Drug Discov 2005, 4:919-927. 10.1038/ nrd1875 16264435
10. Gao ZG Jacobson KA Allosterism in membrane receptors Drug Discov Today 2006, 11:191-202. 10.1016/S1359-6446(05)03689-5 16580596
11. Nagano N Pharmacological and clinical properties of calcimimetics: Calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism Pharmacol Ther 2006, 109:339-365. 10.1016/j.pharmthera.2005.06.019 16102839
12. Hoare SR Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors Drug Discov Today 2005, 10:417-427. 10.1016/ S1359-6446(05)03370-2 15808821
13. Conn PJ Battaglia G Marino MJ Nicoletti F Metabotropic glutamate receptors in the basal ganglia motor circuit Nat Rev Neurosci 2005, 6:787-798. 10.1038/nrn1763 16276355
14. Marino MJ Conn PJ Glutamate-based therapeutic approaches: Allosteric modulators of metabotropic glutamate receptors Curr Opin Pharmacol 2006, 6:98-102. 10.1016/j.coph.2005.09.006 16368268
15. Gao ZG Kim SK IJzerman AP Jacobson KA Allosteric modulation of the adenosine family of receptors Mini Rev Med Chem 2005, 5:545-553. 10.2174/ 1389557054023242 15974932
16. Gao ZG Kim SG Soltysiak KA Melman N IJzerman AP Jacobson KA Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives Mol Pharmacol 2002, 62:81-89. 10.1124/mol.62.1.81 12065758
17. Göblyös A Gao ZG Brussee J Connestari R Santiago SN Ye K IJzerman AP Jacobson KA Structure-activity relationships of 1H-imidazo-[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor J Med Chem 2006, 49:3354-3361. 2547348 16722654 10.1021/jm060086s
18. Lorenzen A Lang H Schwabe U Activation of various subtypes of G-protein alpha subunits by partial agonists of the adenosine A1 receptor Biochem Pharmacol 1998, 56:1287-1293. 10.1016/S0006-2952(98)00207-X 9825727
19. Hall DA Modeling the functional effects of allosteric modulators at pharmacological receptors: An extension of the two-state model of receptor activation Mol Pharmacol 2000, 58:1412-1423. 11093781
20. Gao ZG Kim SK Biadatti T Chen W Lee K Barak D Kim SG Johnson CR Jacobson KA Structural determinants of A3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary J Med Chem 2002, 45:4471-4484. 10.1021/jm020211+ 12238926
21. Kobilka BK G protein coupled receptor structure and activation Biochim Biophys Acta 2007, 1768:794-807. 1876727 17188232 10.1016/ j.bbamem.2006.10.021
22. Jakubík J Bacáková L Lisá V el-Fakahany EE Tucek S Activation of muscarinic acetylcholine receptors via their allosteric binding sites Proc Natl Acad Sci USA 1997, 93:A8705-8709. 10.1073/pnas.93.16.8705
23. Thomas EA Carson MJ Neal MJ Sutcliffe JG Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide Proc Natl Acad Sci USA 1997, 94:14115-14119. 28442 9391162 10.1073/ pnas.94.25.14115
24. Spalding TA Trotter C Skjaerbaek N Messier TL Currier EA Burstein ES Li D Hacksell U Brann MR Discovery of an ectopic activation site on the M(1) muscarinic receptor Mol Pharmacol 2002, 61:1297-1302. 10.1124/ mol.61.6.1297 12021390
25. Langmead CJ Fry VA Forbes IT Branch CL Christopoulos A Wood MD Herdon HJ Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: Direct pharmacological evidence that AC-42 is an allosteric agonist Mol Pharmacol 2006, 69:236-246. 16207821
26. Langmead CJ Christopoulos A Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox Trends Pharmacol Sci 2006, 27:475-481. 10.1016/j.tips.2006.07.009 16889837
27. Kenakin T Allosteric agonist modulators J Recept Signal Transduct Res 2007, 27:247-259. 10.1080/10799890701509000 17885921
28. Schwartz TW Holst B Allosteric enhancers, allosteric agonists and ago-allosteric modulators: Where do they bind and how do they act? Trends Pharmacol Sci 2007, 28:366-373. 10.1016/j.tips.2007.06.008 17629958
29. Thor D Schulz A Hermsdorf T Schöneberg T Generation of an agonistic binding site for blockers of the M3 muscarinic acetylcholine receptor Biochem J 2008, 412:103-112. 10.1042/BJ20071366 18237275
30. Parker EM Ross EM Truncation of the extended carboxyl-terminal domain increases the expression and regulatory activity of the avian beta-adrenergic receptor J Biol Chem 1991, 266:9987-9996. 1851762
31. Strader CD Candelore MR Hill WS Dixon RA Sigal IS A single amino acid substitution in the beta-adrenergic receptor promotes partial agonist activity from antagonists J Biol Chem 1989, 264:16470-16477. 2570781
32. Spalding TA Burstein ES Henderson SC Ducote KR Brann MR Identification of a ligand-dependent switch within a muscarinic receptor J Biol Chem 1998, 273:21563-21568. 10.1074/jbc.273.34.21563 9705286
33. Claude PA Wotta DR Zhang XH Prather PL McGinn TM Erickson LJ Loh HH Law PY Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists Proc Natl Acad Sci USA 1996, 93:5715-5719. 39126 8650158 10.1073/pnas.93.12.5715
34. Joseph CG Wang XS Scott JW Bauzo RM Xiang Z Richards NG Haskell-Luevano C tereochemical studies of the monocyclic agouti-related protein (103-122) Arg-Phe-Phe residues: Conversion of a melanocortin-4 receptor antagonist into an agonist and results in the discovery of a potent and selective melanocortin-1 agonist J Med Chem 2004, 47:S6702-6710. 10.1021/ jm0492756
35. Zahn K Eckstein N Tränkle C Sadée W Mohr K Allosteric modulation of muscarinic receptor signaling: Alcuronium-induced conversion of pilocarpine from an agonist into an antagonist J Pharmacol Exp Ther 2002, 301:720-728. 10.1124/jpet.301.2.720 11961078
36. Kourounakis A Visser C de Groote M IJzerman AP Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor Biochem Pharmacol 2001, 61:137-144. 10.1016/S0006-2952(00)00536-0 11163328
37. Ehlert FJ Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods Mol Pharmacol 1988, 33:187-194. 2828914